{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-132774","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.948750+00:00","generated_at":"2026-05-20T02:30:44.902327+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lyra Therapeutics reports positive ENLIGHTEN 2 Phase 3 trial: LYR-210 meets primary endpoint in CRS (p=0.0078)","bullets":["ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.","Key secondary endpoints met in full population: 3CS (p=0.0209) and SNOT-22 (-8.7, p=0.0101) at 24 weeks; SNOT-22 improvement seen from week 4.","LYR-210 well-tolerated with safety similar to sham; pooled analysis in 64 nasal polyp patients showed positive trends in multiple endpoints.","Company plans to align with FDA on NDA submission in non-polyp patients and continue development in nasal polyp patients.","Effective May 27, 2025, company effected a 1-for-50 reverse stock split (ticker unchanged LYRA)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-132774","json":"https://secwatch.observer/filing/0001193125-25-132774.json","markdown":"https://secwatch.observer/filing/0001193125-25-132774.md","text":"https://secwatch.observer/filing/0001193125-25-132774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/0001193125-25-132774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/d948302d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:30:44.902327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c75bacc668a70007c133d7ab76d13b4c3fd138b","claim":"Lyra Therapeutics, Inc.: Certificate of Amendment to Restated Certificate of Incorporation to effect a 1-for-50 reverse stock split, effective May 27, 2025 at 5:00 p.m. Eastern Time (effective 2025-05-27).","evidence_excerpt":"On May 27, 2025, Lyra Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Restated Certificate of Incorporation, as amended (the “Charter Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), effective May 27, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”)","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000119312525132774/0001193125-25-132774-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-05-27"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}